Infectious Agents and Cancer
Genetic study links Epstein-Barr antibodies to prostate cancer
Across three datasets, genetically predicted antibody levels were linked to higher prostate cancer odds, with a pooled odds ratio of 1.074, versus 1 for no association.Across three datasets, genetically predicted antibody levels were linked to higher prostate cancer odds, with a pooled odds ratio of 1.074, versus 1 for no association.
Mendelian randomizationProstate cancer
Who was studiedProstate cancer cases and controls
What changedHigher Epstein-Barr antibody levels were linked to higher prostate cancer risk (odds ratio 1.074)
The catchThe Epstein-Barr association did not survive correction for testing 37 traits